Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
- DOI
- 10.1016/j.vaccine.2024.126514
- Published
- 2025 Jan 1
- Container
- Vaccine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.vaccine.2024.126514,
title = {Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.},
author = {Jastorff A and Gymnopoulou E and Salas J and Merrall E and Buntinx E and Martin C and Askling HH and Schenkenberger I and Yuste AC and Smith W and Sotolongo R and Von Engelhardt C and Bastian AR and Comeaux C and Ligtenberg N and Callendret B and Heijnen E},
year = {2025},
journal = {Vaccine},
doi = {10.1016/j.vaccine.2024.126514},
url = {https://doi.org/10.1016/j.vaccine.2024.126514}
}RIS
TY - JOUR TI - Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial. AU - Jastorff A AU - Gymnopoulou E AU - Salas J AU - Merrall E AU - Buntinx E AU - Martin C AU - Askling HH AU - Schenkenberger I AU - Yuste AC AU - Smith W AU - Sotolongo R AU - Von Engelhardt C AU - Bastian AR AU - Comeaux C AU - Ligtenberg N AU - Callendret B AU - Heijnen E PY - 2025 JO - Vaccine DO - 10.1016/j.vaccine.2024.126514 UR - https://doi.org/10.1016/j.vaccine.2024.126514 ER -
APA
A, J., E, G., J, S., E, M., E, B., C, M., HH, A., I, S., AC, Y., W, S., R, S., C, V. E., AR, B., C, C., N, L., B, C., & E, H. (2025). Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.. Vaccine. https://doi.org/10.1016/j.vaccine.2024.126514
Source records
- pubmed · retrieved 2026-09-26T04:04:31.700Z